Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytomegalovirus | 44 | 2020 | 79 | 5.170 |
Why?
|
Cytomegalovirus Infections | 30 | 2020 | 82 | 4.270 |
Why?
|
DNA, Viral | 22 | 2020 | 98 | 1.670 |
Why?
|
Antiviral Agents | 19 | 2020 | 136 | 1.240 |
Why?
|
HIV Infections | 12 | 2020 | 997 | 1.160 |
Why?
|
HIV-1 | 6 | 2015 | 451 | 1.040 |
Why?
|
Viral Load | 10 | 2018 | 208 | 1.010 |
Why?
|
Drug Resistance, Viral | 8 | 2014 | 40 | 0.870 |
Why?
|
Ganciclovir | 15 | 2014 | 27 | 0.780 |
Why?
|
Antibodies, Viral | 7 | 2018 | 87 | 0.660 |
Why?
|
Viral Proteins | 9 | 2011 | 24 | 0.620 |
Why?
|
Cervix Uteri | 5 | 2015 | 40 | 0.590 |
Why?
|
Coinfection | 1 | 2015 | 29 | 0.520 |
Why?
|
Immunoglobulin G | 5 | 2018 | 129 | 0.520 |
Why?
|
Humans | 59 | 2020 | 29885 | 0.460 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 5 | 2010 | 14 | 0.440 |
Why?
|
Polymerase Chain Reaction | 6 | 2011 | 165 | 0.430 |
Why?
|
Viremia | 4 | 2015 | 37 | 0.410 |
Why?
|
Antigens, CD | 4 | 2015 | 102 | 0.400 |
Why?
|
Hepatitis B virus | 1 | 2011 | 7 | 0.400 |
Why?
|
Alzheimer Disease | 2 | 2013 | 2005 | 0.400 |
Why?
|
Hepatitis B | 1 | 2011 | 18 | 0.390 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 48 | 0.390 |
Why?
|
Genome, Viral | 3 | 2010 | 12 | 0.380 |
Why?
|
DNA-Directed DNA Polymerase | 8 | 2010 | 9 | 0.360 |
Why?
|
Lung Transplantation | 4 | 2014 | 18 | 0.340 |
Why?
|
Receptors, Cell Surface | 3 | 2015 | 50 | 0.330 |
Why?
|
Reagent Kits, Diagnostic | 2 | 2007 | 19 | 0.310 |
Why?
|
Indicators and Reagents | 1 | 2007 | 13 | 0.300 |
Why?
|
Female | 24 | 2020 | 16473 | 0.290 |
Why?
|
Membrane Glycoproteins | 4 | 2005 | 103 | 0.290 |
Why?
|
Organ Transplantation | 3 | 2010 | 37 | 0.280 |
Why?
|
Virology | 1 | 2006 | 15 | 0.270 |
Why?
|
Viral Envelope Proteins | 4 | 2020 | 22 | 0.270 |
Why?
|
Molecular Sequence Data | 8 | 2006 | 248 | 0.270 |
Why?
|
Drug Resistance, Microbial | 9 | 2002 | 96 | 0.270 |
Why?
|
Chemokines, CXC | 1 | 2006 | 5 | 0.270 |
Why?
|
Reproducibility of Results | 6 | 2011 | 803 | 0.270 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2015 | 16 | 0.270 |
Why?
|
Lipopolysaccharide Receptors | 2 | 2015 | 27 | 0.270 |
Why?
|
Interferon-gamma | 3 | 2015 | 111 | 0.260 |
Why?
|
T-Lymphocytes | 4 | 2013 | 224 | 0.260 |
Why?
|
Hepacivirus | 1 | 2006 | 75 | 0.260 |
Why?
|
Genital Diseases, Female | 1 | 2004 | 10 | 0.240 |
Why?
|
Mutation | 8 | 2009 | 399 | 0.240 |
Why?
|
Base Sequence | 7 | 2009 | 135 | 0.240 |
Why?
|
Microbial Sensitivity Tests | 7 | 2016 | 110 | 0.230 |
Why?
|
Foscarnet | 8 | 2010 | 8 | 0.230 |
Why?
|
Amino Acid Sequence | 6 | 2006 | 196 | 0.220 |
Why?
|
Genes, Viral | 4 | 2016 | 10 | 0.220 |
Why?
|
Virus Replication | 7 | 2020 | 92 | 0.210 |
Why?
|
Herpesvirus 4, Human | 2 | 2020 | 14 | 0.210 |
Why?
|
RNA, Viral | 5 | 2016 | 159 | 0.210 |
Why?
|
Leukocytes | 2 | 2015 | 45 | 0.210 |
Why?
|
Fibroblasts | 5 | 2013 | 93 | 0.200 |
Why?
|
Interleukin-6 | 2 | 2015 | 109 | 0.200 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 558 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2012 | 44 | 0.190 |
Why?
|
Genotype | 5 | 2006 | 407 | 0.190 |
Why?
|
Adult | 13 | 2020 | 8773 | 0.190 |
Why?
|
Male | 17 | 2020 | 15870 | 0.180 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 19 | 0.180 |
Why?
|
DNA Virus Infections | 1 | 2020 | 5 | 0.180 |
Why?
|
RNA Virus Infections | 1 | 2020 | 5 | 0.180 |
Why?
|
RNA Viruses | 1 | 2020 | 5 | 0.180 |
Why?
|
Salicylates | 1 | 2020 | 7 | 0.180 |
Why?
|
DNA Viruses | 1 | 2020 | 6 | 0.180 |
Why?
|
Isoxazoles | 3 | 2010 | 16 | 0.180 |
Why?
|
Viral Fusion Proteins | 1 | 2020 | 16 | 0.180 |
Why?
|
Lymphocyte Activation | 3 | 2013 | 215 | 0.180 |
Why?
|
Receptors, Immunologic | 2 | 2013 | 34 | 0.180 |
Why?
|
Hepatitis C | 2 | 2013 | 66 | 0.170 |
Why?
|
Neurocognitive Disorders | 1 | 2018 | 19 | 0.160 |
Why?
|
Anti-HIV Agents | 2 | 2018 | 173 | 0.160 |
Why?
|
Inflammation | 3 | 2015 | 346 | 0.160 |
Why?
|
Cytosine | 2 | 2010 | 6 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2011 | 46 | 0.150 |
Why?
|
Middle Aged | 11 | 2020 | 9958 | 0.150 |
Why?
|
Strophanthins | 1 | 2016 | 1 | 0.140 |
Why?
|
Methionine | 1 | 2016 | 3 | 0.140 |
Why?
|
Carotid Arteries | 3 | 2012 | 54 | 0.140 |
Why?
|
Open Reading Frames | 3 | 2006 | 12 | 0.140 |
Why?
|
Receptors, Tumor Necrosis Factor, Member 14 | 3 | 2013 | 3 | 0.140 |
Why?
|
Cells, Cultured | 7 | 2015 | 678 | 0.140 |
Why?
|
Biomarkers | 2 | 2018 | 703 | 0.130 |
Why?
|
Raltegravir Potassium | 1 | 2015 | 9 | 0.130 |
Why?
|
Tissue Donors | 1 | 1996 | 73 | 0.130 |
Why?
|
Genetic Variation | 2 | 2009 | 110 | 0.130 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 154 | 0.130 |
Why?
|
Sulfates | 1 | 2015 | 16 | 0.130 |
Why?
|
Organometallic Compounds | 1 | 2015 | 13 | 0.130 |
Why?
|
Interleukin-17 | 1 | 2015 | 27 | 0.130 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 21 | 0.130 |
Why?
|
Interleukins | 1 | 2015 | 37 | 0.130 |
Why?
|
Indoles | 1 | 2015 | 51 | 0.130 |
Why?
|
Anti-Infective Agents, Local | 1 | 2015 | 52 | 0.130 |
Why?
|
Sequence Homology, Amino Acid | 5 | 1999 | 45 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2008 | 92 | 0.120 |
Why?
|
Cell Line | 5 | 2016 | 297 | 0.120 |
Why?
|
Organ Culture Techniques | 3 | 2011 | 29 | 0.120 |
Why?
|
Point Mutation | 1 | 1994 | 29 | 0.120 |
Why?
|
Cohort Studies | 4 | 2018 | 1954 | 0.110 |
Why?
|
Viral Structural Proteins | 1 | 1992 | 4 | 0.110 |
Why?
|
Organophosphonates | 2 | 2010 | 5 | 0.110 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1992 | 19 | 0.110 |
Why?
|
Phylogeny | 3 | 2005 | 63 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2005 | 33 | 0.110 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 88 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2013 | 93 | 0.110 |
Why?
|
Neurofibrillary Tangles | 1 | 2013 | 189 | 0.100 |
Why?
|
Decidua | 1 | 2011 | 1 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2013 | 221 | 0.100 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2011 | 19 | 0.100 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 135 | 0.100 |
Why?
|
Sequence Homology, Nucleic Acid | 3 | 1999 | 16 | 0.100 |
Why?
|
Plasma | 1 | 2011 | 34 | 0.100 |
Why?
|
Vascular Stiffness | 1 | 2011 | 9 | 0.100 |
Why?
|
Amyloid beta-Peptides | 1 | 2013 | 302 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2020 | 146 | 0.100 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 18 | 0.100 |
Why?
|
Green Fluorescent Proteins | 2 | 2008 | 34 | 0.100 |
Why?
|
Genes, Reporter | 2 | 2008 | 29 | 0.100 |
Why?
|
Lymphocyte Subsets | 1 | 2011 | 30 | 0.090 |
Why?
|
Interleukin-8 | 2 | 2007 | 32 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 73 | 0.090 |
Why?
|
Toll-Like Receptors | 2 | 2007 | 27 | 0.090 |
Why?
|
Gene Expression | 4 | 2011 | 232 | 0.090 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 63 | 0.080 |
Why?
|
Artemisinins | 1 | 2008 | 1 | 0.080 |
Why?
|
Skin | 2 | 2003 | 118 | 0.080 |
Why?
|
Betaherpesvirinae | 1 | 2008 | 1 | 0.080 |
Why?
|
Virion | 2 | 2020 | 13 | 0.080 |
Why?
|
Lymphoid Tissue | 1 | 2008 | 21 | 0.080 |
Why?
|
Foreskin | 1 | 2007 | 1 | 0.080 |
Why?
|
Poly I-C | 1 | 2007 | 6 | 0.080 |
Why?
|
Interferon-beta | 1 | 2007 | 7 | 0.080 |
Why?
|
Receptors, Virus | 2 | 2005 | 7 | 0.080 |
Why?
|
Chemokine CXCL1 | 1 | 2007 | 3 | 0.080 |
Why?
|
HIV Core Protein p24 | 1 | 2007 | 29 | 0.080 |
Why?
|
Culture Media | 1 | 2007 | 38 | 0.080 |
Why?
|
Stromal Cells | 1 | 2007 | 35 | 0.070 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 129 | 0.070 |
Why?
|
Phenotype | 3 | 2003 | 363 | 0.070 |
Why?
|
Endothelial Cells | 1 | 2007 | 65 | 0.070 |
Why?
|
HEK293 Cells | 2 | 2020 | 69 | 0.070 |
Why?
|
Nucleic Acid Hybridization | 1 | 1986 | 11 | 0.070 |
Why?
|
Laboratories | 1 | 2006 | 26 | 0.070 |
Why?
|
Genomic Instability | 1 | 2006 | 7 | 0.070 |
Why?
|
Glycosylation | 1 | 2006 | 24 | 0.070 |
Why?
|
Herpesviridae | 1 | 2005 | 2 | 0.070 |
Why?
|
Vaginosis, Bacterial | 1 | 2005 | 31 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 159 | 0.060 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2004 | 1 | 0.060 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2004 | 1 | 0.060 |
Why?
|
Therapeutic Irrigation | 1 | 2004 | 66 | 0.060 |
Why?
|
Saliva | 1 | 2004 | 54 | 0.060 |
Why?
|
Vagina | 1 | 2004 | 51 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 1992 | 131 | 0.060 |
Why?
|
Gene Amplification | 1 | 2003 | 23 | 0.060 |
Why?
|
Aged, 80 and over | 1 | 2013 | 4932 | 0.060 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2003 | 4 | 0.060 |
Why?
|
Aged | 2 | 2014 | 9620 | 0.050 |
Why?
|
Opportunistic Infections | 1 | 2002 | 9 | 0.050 |
Why?
|
Central Nervous System Viral Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
Phosphorylation | 2 | 2013 | 159 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2020 | 644 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2015 | 203 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2001 | 26 | 0.050 |
Why?
|
Models, Biological | 2 | 2015 | 347 | 0.050 |
Why?
|
CD57 Antigens | 2 | 2011 | 5 | 0.050 |
Why?
|
ADP-ribosyl Cyclase 1 | 2 | 2011 | 18 | 0.050 |
Why?
|
HLA-DR Antigens | 2 | 2011 | 26 | 0.050 |
Why?
|
CD28 Antigens | 2 | 2011 | 18 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2016 | 324 | 0.050 |
Why?
|
Animals | 3 | 2020 | 4621 | 0.050 |
Why?
|
Vero Cells | 1 | 2020 | 7 | 0.050 |
Why?
|
DNA Replication | 1 | 2020 | 12 | 0.050 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2013 | 2 | 0.050 |
Why?
|
Virus Internalization | 1 | 2020 | 17 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 98 | 0.040 |
Why?
|
Risk Factors | 3 | 2014 | 2466 | 0.040 |
Why?
|
Astrocytes | 1 | 2020 | 122 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 455 | 0.040 |
Why?
|
Mental Status and Dementia Tests | 1 | 2018 | 81 | 0.040 |
Why?
|
Mucous Membrane | 2 | 2009 | 40 | 0.040 |
Why?
|
Signal Transduction | 2 | 2013 | 491 | 0.040 |
Why?
|
Cardiac Glycosides | 1 | 2016 | 1 | 0.040 |
Why?
|
Genes, Immediate-Early | 1 | 2016 | 2 | 0.040 |
Why?
|
Biological Transport, Active | 1 | 2016 | 18 | 0.040 |
Why?
|
Molecular Structure | 1 | 2016 | 28 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 43 | 0.040 |
Why?
|
Time Factors | 3 | 2011 | 1642 | 0.040 |
Why?
|
Restriction Mapping | 1 | 1996 | 5 | 0.040 |
Why?
|
Sequence Alignment | 1 | 1996 | 22 | 0.040 |
Why?
|
DNA Primers | 1 | 1996 | 54 | 0.040 |
Why?
|
Models, Molecular | 1 | 2016 | 81 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 1992 | 37 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2002 | 957 | 0.030 |
Why?
|
Complement Inactivator Proteins | 1 | 1995 | 1 | 0.030 |
Why?
|
CD55 Antigens | 1 | 1995 | 2 | 0.030 |
Why?
|
CD59 Antigens | 1 | 1995 | 3 | 0.030 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 1995 | 12 | 0.030 |
Why?
|
Immunization | 1 | 2015 | 47 | 0.030 |
Why?
|
Administration, Intravaginal | 1 | 2015 | 1 | 0.030 |
Why?
|
Cell Lineage | 1 | 2015 | 30 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 854 | 0.030 |
Why?
|
Cell Separation | 1 | 2015 | 42 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2015 | 85 | 0.030 |
Why?
|
Cell Survival | 1 | 2015 | 163 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 266 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2015 | 148 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 970 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2015 | 90 | 0.030 |
Why?
|
Conserved Sequence | 1 | 1994 | 7 | 0.030 |
Why?
|
Risk Assessment | 2 | 2010 | 685 | 0.030 |
Why?
|
Simplexvirus | 2 | 1999 | 9 | 0.030 |
Why?
|
CD56 Antigen | 1 | 2013 | 8 | 0.030 |
Why?
|
Lymphotoxin-alpha | 1 | 2013 | 7 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 17 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 22 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2013 | 26 | 0.030 |
Why?
|
Interferon Type I | 1 | 2013 | 19 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2013 | 68 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2015 | 3557 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 112 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1992 | 32 | 0.030 |
Why?
|
Demography | 1 | 2013 | 78 | 0.030 |
Why?
|
Plasmids | 1 | 1992 | 42 | 0.030 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 1992 | 7 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 55 | 0.030 |
Why?
|
Transfection | 1 | 1992 | 128 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2013 | 95 | 0.030 |
Why?
|
Antigens, Viral | 3 | 1998 | 19 | 0.030 |
Why?
|
Tunica Intima | 1 | 2012 | 27 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2011 | 28 | 0.020 |
Why?
|
Cellular Senescence | 1 | 2011 | 18 | 0.020 |
Why?
|
Fetal Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
Off-Label Use | 1 | 2010 | 7 | 0.020 |
Why?
|
Models, Statistical | 1 | 2011 | 133 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 494 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2010 | 37 | 0.020 |
Why?
|
Pregnancy | 1 | 2011 | 410 | 0.020 |
Why?
|
Palatine Tonsil | 1 | 2009 | 7 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 174 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 223 | 0.020 |
Why?
|
Rectum | 1 | 2009 | 61 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2009 | 216 | 0.020 |
Why?
|
Ultrasonography | 1 | 2011 | 227 | 0.020 |
Why?
|
Endothelium, Vascular | 2 | 1999 | 64 | 0.020 |
Why?
|
Young Adult | 1 | 2014 | 1968 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2010 | 3325 | 0.020 |
Why?
|
Virus Shedding | 1 | 2007 | 15 | 0.020 |
Why?
|
Ligands | 1 | 2007 | 58 | 0.020 |
Why?
|
Lymphocytes | 1 | 2008 | 110 | 0.020 |
Why?
|
Deoxyribonuclease BamHI | 1 | 1986 | 1 | 0.020 |
Why?
|
DNA Restriction Enzymes | 1 | 1986 | 4 | 0.020 |
Why?
|
Herpesvirus 1, Human | 1 | 2005 | 2 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2005 | 29 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 1837 | 0.020 |
Why?
|
Binding Sites | 1 | 2005 | 75 | 0.020 |
Why?
|
Immunity, Mucosal | 1 | 2005 | 29 | 0.020 |
Why?
|
Toll-Like Receptor 2 | 1 | 2005 | 32 | 0.020 |
Why?
|
Toll-Like Receptor 4 | 1 | 2005 | 33 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2004 | 11 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2004 | 8 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2004 | 15 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2004 | 60 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 273 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2004 | 57 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2005 | 177 | 0.010 |
Why?
|
Child | 1 | 2008 | 1379 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 92 | 0.010 |
Why?
|
Transplantation Immunology | 1 | 2002 | 4 | 0.010 |
Why?
|
Probability | 1 | 2002 | 94 | 0.010 |
Why?
|
Infant | 1 | 2004 | 542 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 142 | 0.010 |
Why?
|
Drug Resistance | 1 | 2002 | 58 | 0.010 |
Why?
|
Viral Plaque Assay | 2 | 1992 | 2 | 0.010 |
Why?
|
Graft Rejection | 1 | 2002 | 75 | 0.010 |
Why?
|
Graft Survival | 1 | 2002 | 98 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 232 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 247 | 0.010 |
Why?
|
Survival Rate | 1 | 2002 | 377 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2002 | 279 | 0.010 |
Why?
|
Umbilical Veins | 1 | 1999 | 3 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1999 | 27 | 0.010 |
Why?
|
Codon | 1 | 1999 | 8 | 0.010 |
Why?
|
Virulence | 1 | 1999 | 15 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1999 | 107 | 0.010 |
Why?
|
Uridine | 1 | 1999 | 2 | 0.010 |
Why?
|
Drug Resistance, Multiple | 1 | 1999 | 12 | 0.010 |
Why?
|
Immediate-Early Proteins | 1 | 1998 | 6 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2002 | 1855 | 0.010 |
Why?
|
Rats | 1 | 1999 | 869 | 0.010 |
Why?
|
Phosphonoacetic Acid | 1 | 1992 | 1 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1991 | 34 | 0.010 |
Why?
|